Core Viewpoint - Evofem Biosciences has entered a License and Supply Agreement with Windtree Therapeutics to reduce the manufacturing cost of its contraceptive product PHEXXI by 55% to 60%, enabling global expansion into price-sensitive markets [1][2][3] Group 1: Cost Reduction and Manufacturing - The cost of goods sold (COGS) for PHEXXI is expected to decrease significantly due to Windtree leveraging its manufacturing contacts [2] - There will be no cost incurred by Evofem for the technology transfer to the new manufacturer [2] Group 2: Global Expansion Strategy - Evofem aims to expand PHEXXI into new international markets where there is a demand for non-hormonal contraceptives, addressing unmet needs in women's reproductive health [3] - The reduction in manufacturing costs is seen as a critical step to make PHEXXI commercially viable in markets outside the U.S. [3] Group 3: Product Overview and Recent Developments - PHEXXI is a hormone-free contraceptive vaginal gel that is applied before intercourse, designed to maintain a vaginal environment that is inhospitable to sperm [4] - In July 2024, Evofem expanded its product offerings by acquiring SOLOSEC, an FDA-approved oral antibiotic for treating bacterial vaginosis and trichomoniasis [5]
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics